Drugs / AD-224A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06291207 | Apr 2024 → Jul 2025 overdue | essential hypertension | Addpharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-224A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06291207 ↗ |
| Route | Oral | “PO, Once daily, 8weeks” NCT06291207 ↗ |